Ngenebio

In vitro cancer diagnostic products

placeSeoul, Seoul, South Korea calendar_todayFounded 2015 groups124 employees language ngenebio.com

Innovation

23 patent families (11 granted) — focus: Physics & computing, Chemistry & metallurgy; filing pace slowing. Cited 211 times.

YearFilings
20171
20181
20196
20204
20216
20223
20239
20241
20251

Social engagement

Social engagement: 1.5K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

5 investors on record; lead investors include Korea Investment Holdings; 1 has since exited.

Investor typeCountShare
Venture capital240%
Private equity120%
Bank & private debt120%
Other / undisclosed120%

Hiring activity

Hires occasionally

1 role tracked across 1 of the last 12 months

8 Apr 2026 · Diagnostic Business Sales Manager

Based on job postings tracked across public sources.

Recent activity

8 Apr 2026
Milestone
Seoul St. Mary's Hospital
12 Feb 2026
Event
S2D53, WHX Labs Dubai 2026
11 Feb 2026
Event
WHX Labs 2026
Coming soon